Table 2.

Oxylipin metabolite differences between IgA nephropathy patients whose kidney function improved compared with those whose kidney function did not improve

Oxylipin (nmol/L)	Post-supplementationa,b
	Non-Improved		Improved		p-value
	Mean	SE	Mean	SE
Total oxylipins	96,000	19,000	50,000	6,200	0.01
Total 12/15-LOX	43,000	5,200	25,000	2,700	0.01
Total 5-LOX	42,000	8,400	24,000	3,800	0.04
9-HODE	18,000	3,500	9,500	1,500	0.03
13-HODE	17,000	4,000	8,100	1,500	0.03
9-HETE	4,900	1,400	2,100	370	0.03
11-HETE	4,600	1,000	1,900	360	0.02
8,15-DiHETE	4,300	1,200	1,700	270	0.02
12-HETE	3,100	830	1,200	230	0.01
8-HETE	2,400	770	950	160	0.03
15-oxo-ETE	1,600	470	690	100	0.03
6-trans-LTB4	660	75	420	84	0.04
9,12,13-TriHOME	530	180	200	40	0.03
13-HOTrE	500	120	130	31	0.01
Total COX	380	54	220	32	0.02
9-HOTrE	320	82	92	13	0.01
11,12-,15-TriHETrE	240	99	86	15	0.03
LXA4	120	21	74	6.3	0.03
PGD2	87	13	47	16	0.02
PGB2	39	7.8	16	2.4	0.005
PGF2α	26	5.3	13	2.1	0.02
EKODE	25	6.6	10	1.8	0.04
LTB4	19	2.7	11	1.6	0.02
PGD1	17	1.7	11	3.0	0.04
PGE3	8.3	2.0	3.4	1.1	0.04
11(12)-EpETrE/DiHETrE	5.0	0.62	3.3	0.62	0.03
14(15)-EpETrE/DiHETrE	4.2	0.79	2.5	0.42	0.03
20-OH-LTB4	3.4	0.89	1.2	0.37	0.03
14(15)-EpETrE	2.6	0.40	1.7	0.18	0.04
8(9)-EpETrE	1.9	0.31	1.0	0.21	0.02
8(9)-EpETrE/DiHETrE	1.6	0.16	0.72	0.17	0.01

^aMetabolites significantly different by t-test comparison of patients whose kidney function was improved >25% as measured by UP/C ratios (i.e., ≤25% change in UP/C from baseline to 24 months) and patients whose kidney function did not improve (i.e., ≥25% change in UP/C from baseline to 24 months)

^bEp, epoxy; ODE, octadecadienoic acid; DiH, dihydroxy; ODE, octadecadienoic acid; ETrE, eicosatrienoic acid; ETE, eicosatetraenoic acid; DPE, docosapentaenoic acid; PG, prostaglandin; LX, lipoxin; OME, octadecamonoenoic acid; LT, leukotriene; TX, thromboxane; TriH; trihydroxy; EPE, eicosapentaenoic acid; COX, cyclooxygenase; and LOX, lipoxygenase